STOCK TITAN

Amesite Inc. (AMST) CEO buys common shares plus Series A-1 and A-2 warrants

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Amesite Inc. director and chief executive officer Ann Marie Sastry reported buying additional equity on April 28, 2026. She purchased 174,216 shares of common stock at $1.435 per share in a private placement pursuant to a securities purchase agreement and now holds 1,049,647 common shares directly. On the same date, she also acquired Series A-1 and Series A-2 warrants, each covering 174,216 underlying common shares at a $1.435 exercise price, with expirations on April 28, 2031 and October 28, 2027, respectively.

Positive

  • None.

Negative

  • None.
Insider Sastry Ann Marie
Role CHIEF EXECUTIVE OFFICER
Bought 522,648 shs ($250K)
Type Security Shares Price Value
Purchase Series A-1 Warrants (right to buy) 174,216 $0.00 --
Purchase Series A-2 Warrants (right to buy) 174,216 $0.00 --
Purchase Common Stock 174,216 $1.435 $250K
Holdings After Transaction: Series A-1 Warrants (right to buy) — 174,216 shares (Direct, null); Series A-2 Warrants (right to buy) — 174,216 shares (Direct, null); Common Stock — 1,049,647 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Common shares purchased 174,216 shares Common Stock bought on April 28, 2026 at $1.435
Purchase price per share $1.435 per share Price for 174,216 common shares on April 28, 2026
Common shares after transaction 1,049,647 shares Total Amesite common stock directly held after April 28, 2026
Series A-1 warrants acquired 174,216 warrants Series A-1 Warrants, each for one common share
Series A-2 warrants acquired 174,216 warrants Series A-2 Warrants, each for one common share
Warrant exercise price $1.435 per share Exercise price for Series A-1 and A-2 warrants
Series A-2 warrant expiration October 28, 2027 Expiration date of Series A-2 Warrants
Series A-1 warrant expiration April 28, 2031 Expiration date of Series A-1 Warrants
private placement transaction financial
"The shares were purchased in a private placement transaction pursuant to a securities purchase agreement."
securities purchase agreement financial
"The shares were purchased in a private placement transaction pursuant to a securities purchase agreement."
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
424(b)(5) prospectus supplement regulatory
"please refer to the 424(b)(5) prospectus supplement filed by Amesite Inc. with the SEC on April 28, 2026."
Series A-1 Warrants financial
"Series A-1 Warrants (right to buy)"
Series A-1 warrants are tradable instruments that give their holder the right, but not the obligation, to buy a company’s shares at a preset price for a limited time; they are typically issued alongside a specific financing round labeled “Series A-1.” Think of them like a coupon that lets an investor buy stock at a locked-in price later — if the company’s share price rises above that price the coupon becomes valuable, otherwise it may expire worthless. For investors they matter because exercising warrants can increase potential upside while also diluting existing shareholders and affecting future ownership percentages and share value.
Series A-2 Warrants financial
"Series A-2 Warrants (right to buy)"
Series A-2 warrants are a specific class of long‑term options issued by a company that give the holder the right to buy a set number of shares at a pre‑agreed price. Think of them as a coupon for future stock purchases: they can add potential value for the holder if the share price rises, but they also represent potential dilution for existing shareholders and can affect an investor’s ownership and returns when exercised or converted.
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sastry Ann Marie

(Last)(First)(Middle)
C/O AMESITE INC.
607 SHELBY STREET, SUITE 700 PMB 214

(Street)
DETROIT MICHIGAN 48226

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Amesite Inc. [ AMST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CHIEF EXECUTIVE OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/28/2026P174,216A$1.435(1)1,049,647D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A-1 Warrants (right to buy)$1.43504/28/2026P174,21604/28/202604/28/2031Common Stock174,216$0174,216D
Series A-2 Warrants (right to buy)$1.43504/28/2026P174,21604/28/202610/28/2027Common Stock174,216$0174,216D
Explanation of Responses:
1. The shares were purchased in a private placement transaction pursuant to a securities purchase agreement. For more information relating to the offering pursuant to which the reported shares were purchased, please refer to the 424(b)(5) prospectus supplement filed by Amesite Inc. with the SEC on April 28, 2026.
/s/ Ann Marie Sastry05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Amesite Inc. (AMST) report in this Form 4?

Amesite Inc. reported that CEO and director Ann Marie Sastry bought 174,216 common shares and acquired Series A-1 and A-2 warrants, each for 174,216 underlying shares, all dated April 28, 2026, as part of a private placement transaction.

How many Amesite (AMST) common shares does the CEO hold after these transactions?

After the reported transactions, CEO Ann Marie Sastry directly holds 1,049,647 shares of Amesite common stock. This reflects the addition of 174,216 newly purchased shares on April 28, 2026, in the private placement described in the Form 4 footnote.

What price did Amesite’s CEO pay for the newly purchased AMST common shares?

The CEO paid $1.435 per share for 174,216 Amesite common shares. These were purchased on April 28, 2026, in a private placement transaction pursuant to a securities purchase agreement referenced in a 424(b)(5) prospectus supplement.

What are the key terms of Amesite (AMST) Series A-1 and A-2 warrants acquired by the CEO?

The CEO acquired Series A-1 and Series A-2 warrants, each covering 174,216 underlying Amesite common shares at a $1.435 exercise price. The Series A-2 warrants expire on October 28, 2027, and the Series A-1 warrants expire on April 28, 2031.

Was Amesite’s CEO open-market buying or participating in a private placement?

Although coded as purchases, the footnote specifies the CEO’s transactions were part of a private placement under a securities purchase agreement. The footnote directs investors to Amesite’s 424(b)(5) prospectus supplement filed on April 28, 2026, for additional offering details.

How many total securities did Amesite’s CEO acquire in this Form 4 period?

Across all reported transactions, the CEO acquired 174,216 common shares and two warrant series, each for 174,216 underlying shares. Transaction summary data shows three buy transactions totaling 522,648 units, including both common stock and warrant positions.